Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626) Table 3: Primary outcomes of two different high-intensity atorvastatin doses in patients with acute coronary syndrome (N= 626)
Outcome
Atorvastatin 40mg Users (N= 475) n (%) Atorvastatin 80mg Users (N= 151) n (%) Hazard Ratio 95% CI
P-value
Adjusted Hazard Ratio 95% CI
P-value
Primary endpoint at 1 month
4 (0.8)
2 (1.3)
0.60 (0.10-3.30)
0.551
0.59 (0.04-8.13)
0.690
CVD-associated death, non-fatal ACS, and non-fatal stroke
Primary endpoint at 12 months
15 (3.2)
6 (4.0)
0.58 (0.22-1.50)
0.243
0.57 (0.18-1.80)
0.340
CVD-associated death, non-fatal ACS, and non-fatal stroke
CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome CVD: cardiovascular disease; ACS: acute coronary syndrome